Epidemiological Study of Male Genito-urinary Malignancies at Clinical Oncology Department Tanta University Hospitals

Mai Hashem Fayed\*, Asmaa Mohamed El-Kady, Hanan Shawky Mahmoud, Hesham Ahmed Tawfik

Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt

\*Email. [maiihashem3@gmail.com](mailto:maiihashem3@gmail.com)

Abstract: Background: Genitourinary cancers, in particular carcinoma of the kidneys, bladder, and prostate take a large toll on human health and placed significant economic burden on health care systems. The aim of this work was to determine the burden of male genito-urinary malignancy, describe the clinico-pathological pattern of all male genito-urinary tumors and find tools for screening and early diagnosis. Methods: This retrospective hospital based epidemiological study was carried out on 610 patients who were histopathologically proved to have male genito-urinary malignanc. All patients were subjected to: Patient evaluation through careful history taking, general examination and local examination. Investigations including: Pathological finding, laboratory investigations and radiological investigations. Results: Bladder cancer ranked the first among other types of male genito-urinary cancers. The second was prostate cancer followed by kidney cancer then testicular cancer. the age group (61-80) years is the most common age group affected by male genitourinary cancers followed by the age group (41-60) years. The mean age of male genitourinary cancers was 66.7 years with a median age of 67 years. The majority of cases were from two administrative areas; Tanta and Al-Mahalla El-Kobra, the total percentage from Tanta & Al-Mahalla El-kobra represented nearly 80% of the studied patients. The most common co-morbidities were hypertension, diabetes mellitus and liver cirrhosis. Most of the male genitourinary cancer patients were smokers with negative family history. The most common male genitourinary cancer affected by bilhareziasis was the bladder cancer. Conclusions: We conclude that the most common types of male genito-urinary malignancies included: bladder cancer, prostate cancer, kidney cancer, testicular cancer. The most common histo-pathological subtype in bladder cancer was transitional cell carcinoma, while in prostate cancer was prostatic adenocarcinoma, in kidney cancer was renal cell carcinoma and in testicular cancer was seminoma.

**[**Mai Hashem Fayed, Asmaa Mohamed El-Kady, Hanan Shawky Mahmoud, Hesham Ahmed Tawfik. **Epidemiological Study of Male Genito-urinary Malignancies at Clinical Oncology Department Tanta University Hospitals**. Cancer Biology 2022;12(2):23-34]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). <http://www.cancerbio.net>  [4. doi](http://www.sciencepub.net/nature.%20%20x.doi):[10.7537/marscbj120222.04.](http://www.dx.doi.org/10.7537/marscbj120222.04)

**Keywords:** Bladder Cancer, Prostate Cancer, Kidney Cancer, Testicular Cancer

1. Introduction:

Genitourinary cancers, in particular carcinoma of the kidneys, bladder, and prostate take a large toll on human health and placed significant economic burden on health care systems [1].

According to Globocan 2018, the global incidence of prostate cancer was 7.1%, bladder cancer 3%, kidney cancer 2.2% & testicular cancer 0.4 % in all tumors [2]. In Egypt, according to incidence rate, the bladder cancer is the fourth tumor and represent 7.2% of all tumors incidence, prostate cancer rank 9 in all tumors and represent 4.2%, kidney cancer rank 15 and represent 1.5%, testicular cancer rank 30 and represent 0.17% , cancer of penis rank 35 and represent 0.01% of all tumors incidence [3].

As regard bladder cancer, there are two predominant histologic types of urinary bladder cancer, urothelial cell and squamous cell carcinoma (SCC). Cigarette smoking, occupational exposures to carcinogens, and chronic infection with Schistosoma haematobium have been established as risk factors for bladder cancer [4]**.**

As regard prostate cancer, Adenocarcinoma of the prostate comprises 95% of the malignant neoplasms in this organ. Most prostate cancers arise in the peripheral zone (70-75%), with only 10-15% occurring in the transition zone and ~10% in the central zone. There are three well-established risk factors for Prostate cancer, namely age, family history, and ethnic origin [5].

As regard kidney cancer, Kidney cancer may arise from the renal parenchyma or renal pelvis. Renal pelvic carcinomas are urothelial in origin and share common characteristics with other tumors arising from the urothelium. On the other hand, RCCs can be classified broadly into clear cell and non-clear cell carcinomas; non-clear cell histology includes papillary carcinoma, chromophobe carcinoma and collecting duct carcinoma in addition to some other rarer variants [6]

Risk factors of RCC are divided into controllable (environmental) or uncontrollable. Environmental risk factors include cigarette smoking, obesity, diet, and hypertension. Uncontrollable risk factors include family history and the need for dialysis because of renal disease [7]

As regard testicular tumors, it can be classified into three categories: germ cell tumours, cord stromal tumours, and miscellaneous germ cell/sex cord stromal tumors. risk factors include History of cryptorchidism, Klinefelter syndrome, Testicular cancer in first-grade relatives, Contralateral tumour, testicular intraepithelial neoplasm (TIN) or infertility [8].

The aim of this work was to determine the burden of male genito-urinary malignancy, describe the clinico-pathological pattern of all male genito-urinary tumors and find tools for screening and early diagnosis.

2. Patients and Methods:

This retrospective hospital based epidemiological study was carried out on 610 patients who were histopathologically proved to have male genito-urinary malignancies at Clinical Oncology Department Tanta university Hospital through the period from Aug 2014 to Sep 2019.

An informed written consent was obtained from the patient or relatives of the patients. The study was done after approval from the Ethical Committee Tanta University Hospitals.

Exclusion criteria were patients less than 18 years old, male patients with second primary rather than genito-urinary tract malignancies.

All patients were subjected to: Careful history taking (Personal history, history of the illness, family history, Past history and others co-morbidity), general examination which include general appearance, vital signs, head &neck, chest, upper and lower limb examination and local examination which include abdomen and pelvic examination, investigations including: Pathological finding (Pathologically proven genito-urinary tumors), laboratory investigations (Complete blood picture, kidney function tests, liver function tests, urine analysis and urine cytology in bladder cancer) and tumor marker e.g. PSA in prostate cancer and LDH, AFP & HCG in testicular cancer and radiological investigations (Chest radio-graph, Ultrasound / TRUS, CT/MRI abdomen and pelvis, bone scan).

**Assessment of tumor response:**

A tumor response assessment was performed after treatment according to RECIST criteria version 1.1 [9]. Tumor response was assessed by CT scan and /or MRI for all patients one week after last cycle of chemotherapy & 4weeks after the end of CCRTH to evaluate the radiological response. Cystoscopy and biopsy were performed for patients who achieved a complete radiological response to confirm the pathological response.

**Recist criteria**

A clinical complete response (CR): was defined as the complete disappearance of the intravesical lesion and normalization of the computed tomography findings pathological complete response is confirmed by cystoscopic biopsy in case of clinical complete response.

A partial response (PR): was defined as a 50% decrease in the sum of the products of two perpendicular diameters of all measurable lesions for a minimum of 4 weeks with no increase of 25% in the size of any single lesion.

Progressive disease (PD): if any new lesion appeared, if the tumor size increased 25% greater than the pre-treatment measurements, or in the case of deterioration in clinical status consistent with disease progression.

Stable disease (SD): patients whose findings did not meet the criteria of CR, PR, or PD and who could be followed for at least 2 months were classified as having stable disease.

Statistical analysis

Statistical analysis was done by SPSS v21 (IBM Inc., Chicago, IL, USA). Quantitative variables were presented as mean and standard deviation (SD). Qualitative variables were presented as frequency and percentage (%).

3. Results:

Table 1 show that distribution of studied patients according to tumor site, age groups, administrative area in Gharbia Governorate, comorbidities, marital status, family history and risk factors.

Table 2 shows distribution of bladder cancer patients according to age, histopathological subtype, and disease stage, treatment approach, treatment response according to treatment modality, overall survival and disease-free survival in bladder cancer.

Table 3 shows Distribution of prostate cancer patients according to age, histopathological subtypes, Gleason score, PSA level, stage, treatment approach, treatment response according to treatment modality, overall survival and disease-free survival in kidney cancer.

Table 4 shows distribution of kidney cancer patients according to age, pathological subtypes, stage, treatment approach, treatment response according to treatment modality, overall survival and disease-free survival in kidney cancer

Table 1: Distribution of studied patients according to tumor site, age groups, 464 studied patients in Gharbia Governorate by administrative area, comorbidities, marital status, family history and risk factors.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Type of cancer** | | **2014**  **n =92** | **2015**  **n =103** | **2016**  **n =85** | **2017**  **n =134** | **2018**  **n =131** | **2019**  **n =65** | | **Total**  **n =610** |
| **Bladder** | | 48(52.1%) | 54(52.4%) | 40(47%) | 63(47%) | 62(47.3%) | 37(56.9%) | | 304(49.8%) |
| **Prostate** | | 31(33.6%) | 38(36.8%) | 34(40%) | 59(44%) | 61(46.5%) | 23(35.3%) | | 246(40.3%) |
| **Kidney** | | 10(10.8%) | 10(9.7%) | 11(12.9%) | 9(6.7) | 7 (5.3%) | 3(4.6%) | | 50(8.2%) |
| **Testis** | | 3(3.2%) | 1(0.97%) | 0(0%) | 3(2.2%) | 1(0.76%) | 2(3%) | | 10(1.6%) |
| **Distribution according to age** | | | | | | | | | |
| **Age group (Years)** | | 20-40 | 41-60 | 61-80 | >80 | 66.7 ±10 | | | |
| **Number n =610** | | 15 (2.4%) | 128 (20.9%) | 431(20.7%) | 36 (5.9%) |
| **Distribution in Gharbia Governorate** | | | | | | | | | |
| **Gharbia Governorate** | | **Tanta** | **Al-Mahalla El-kobra** | **Kafr-ElZiat** | **Al-Santa** | **Kotor** | **Bassune** | **Smanoud** | |
| **Total (n =464)** | | 202(43.5%) | 174(37.5%) | 24(5.2%) | 20(4.3%) | 18(3.9%) | 14(3%) | 12(2.6%) | |
| **Comorbidity** | | | **Prostate**  **(n =246)** | **Bladder**  **(n =304)** | **Kidney**  **(n =50)** | **Testis**  **(n =10)** | **Total**  **(n =610)** | | |
| **DM** | | | 60 (24.4%) | 63 (20.7%) | 11 (22%) | 2 (20%) | 136 (22.3%) | | |
| **HTN** | | | 70 (28.5%) | 82 (27%) | 13 (26%) | 3 (30%) | 168 (27.5%) | | |
| **Cardiac** | | | 12 (4.9%) | 21 (6.9%) | 5(10%) | 1 (10%) | 39 (6.4%) | | |
| **Multiple co morbidity**  **(DM, HTN, cardiac)** | | | 53 (21.5%) | 43 (14%) | 2(4%) | 0 (0%) | 98 (16%) | | |
| **Cirrhotic** | | | 31(12.6%) | 55 (18.1%) | 16(32%) | 4 (40%) | 106 (17.4%) | | |
| **Renal** | | | 1 (0.4%) | 3 (1%) | 0 (0%) | 0 (0%) | 4 (0.7%) | | |
| **Unregistered** | | | 19 (7.7%) | 37 (12.2%) | 3 (6%) | 0 (0%) | 59 (9.6%) | | |
| **Characteristics** | | | **Prostate**  **(n =246)** | **Bladder**  **(n =304)** | **Kidney**  **(n =50)** | **Testis**  **(n =10)** | **Total**  **(n =610)** | | |
| **Marital status** | **Single** | | 1 (0.4%) | 0 (0%) | 0 (0%) | 1 (10%) | 2 (0.3%) | | |
| **Married** | | 229 (93%) | 282(92.8%) | 46 (92%) | 9 (90%) | 566 (92.8%) | | |
| **Widow** | | 3 (1.2%) | 2 (0.7%) | 0 (0%) | 0 (0%) | 5 (0.8%) | | |
| **Divorced** | | 0 (0%) | 1 (0.3%) | 0 (0%) | 0 (0%) | 1 (0.2%) | | |
| **Unregistered** | | 13 (5.3%) | 19 (6.25) | 4 (8%) | 0 (0%) | 36 (5.9%) | | |
| **Risk factors** | **Smoker** | | 106 (43.1%) | 128(42.1%) | 17 (34%) | 2 (20%) | 253 (41.5%) | | |
| **Bilharziasis** | | 0 (0%) | 23(7.6%) | 0 (0%) | 0 (0%) | 23(3.8%) | | |
| **Smoking & bilharziasis** | | 0 (0%) | 14(4.6%) | 0 (0%) | 0 (0%) | 14 (2.3%) | | |
| **No risk factors** | | 140 (56.9%) | 139(45.7%) | 33 (66%) | 8 (80%) | 320 (52.5%) | | |
| **Family history** | **Positive** | | 14 (5.7%) | 18(5.9%) | 4 (8%) | 1 (10%) | 37 (61.1%) | | |
| **Negative** | | 232 (94.3%) | 286(94.1%) | 46 (92%) | 9 (90%) | 573 (93.9%) | | |

Data was presented as Mean ± SD

Table 2: Distribution of bladder cancer patients according to age, histopathological subtype and disease stage, treatment, treatment response in bladder cancer according to treatment modality, overall survival and disease-free survival in bladder cancer

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Age group(years)** | | **Total (n =304)** | | | | | | |
| 20-40 | | 5 (1.6%) | | | | | 65.9 ± 9.4 | |
| 41-60 | | 76 (25%) | | | | |
| 61-80 | | 207 (68.1%) | | | | |
| >80 | | 16 (5.3%) | | | | |
| **Histopathological subtype** | | | | | | | | |
| **Transitional cell carcinoma** | | 292 (96.1%) | | | | | | |
| **Squamous cell carcinoma** | | 8 (2.6%) | | | | | | |
| **Adenocarcinoma** | | 2 (0.7%) | | | | | | |
| **Sarcoma** | | 1 (0.3%) | | | | | | |
| **Anaplastic carcinoma** | | 1 (0.3%) | | | | | | |
| **Stage** | | | | | | | | |
| **Stage I** | | | 24 (7.89%) | | | | | |
| **Stage II** | | | 57 (18.75%) | | | | | |
| **Stage III** | | | 79 (25.98%) | | | | | |
| **Stage IV** | | | 144 (47.36%) | | | | | |
| **Treatment** | | | | | | | | |
| **Surgery** | **TUR** | | 267 (87.83%) | | | | | |
| **Maximum TUR** | | 30 (9.87%) | | | | | |
| **Radical Cystectomy** | | 7 (2.30%) | | | | | |
| **BCG** | | | 10 (3.29%) | | | | | |
| **Radiotherapy** | | | 56 (18.42%) | | | | | |
| **Chemotherapy** | | | 127 (41.77%) | | | | | |
| **Combined chemo and radiotherapy** | | | 125 (41.18%) | | | | | |
| **Treatment response** | | | **Overall** | **Complete** | **Partial** | **Stable disease** | | **Progressive disease** |
| **Radiotherapy** | | | 46 (15.13%) | 19 (6.25%) | 27 (8.88%) | 6 (10.71%) | | 4 (7.14%) |
| **Chemotherapy** | | | 87 (28.62%) | 21 (6.91%) | 66 (21.71%) | 27 (21.26%) | | 13 (10.24%) |
| **Combined radio**  **and chemotherapy** | | | 117 (38.49%) | 66 (21.71%) | 51 (16.78%) | 5 (4%) | | 3 (2.40%) |
| Years | | | **overall survival (%)** | | **Disease free survival (%)** | | | |
| 2 -year | | | 62.17% | | 56.58% | | | |
| 3 -year | | | 58.5% | | 51.31% | | | |
| 5 -year | | | 50.65 % | | 47.37% | | | |

Data was presented as Mean ± SD

Table 3: Distribution of prostate cancer patients according to age, histopathological subtypes, Gleason score, PSA level, stage, treatment approach, treatment response according to treatment modality, overall survival and disease-free survival in kidney cancer

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Age group (year)** | **Total (n =246)** | | | | | | | | |
| 20-40 | 0 (0%) | | | | 70.2 ± 7.7 | | | | |
| 41-60 | 30 (20.5%) | | | |
| 61-80 | 196 (79.7%) | | | |
| >80 | 20 (8.1%) | | | |
| **Pathology** | | | | | | | | | |
| **Adenocarcinoma** | 244 (99.2%) | | | | | | | | |
| **Neuroendocrine** | 1 (0.4%) | | | | | | | | |
| **Anaplastic carcinoma** | 1 (0.4%) | | | | | | | | |
| **Gleason Score** | ≤6 | | 7 | | | | | 8-10 | |
| 41 (16.6%) | | 87 (35.4%) | | | | | 118 (48%) | |
| **PSA level**  **(ng/ml)** | <10 | | 10-20 | | | | | >20 | |
| 3(1.22%) | | 19(7.72%) | | | | | 224 (91.06%) | |
| **Stage** | | | | | | | | | |
| **Stage I** | 1 (0.4%) | | | | | | | | |
| **Stage II** | 29 (11.8%) | | | | | | | | |
| **Stage III** | 30 (12.2%) | | | | | | | | |
| **Stage IV** | 186 (75.6%) | | | | | | | | |
| **Treatment** | | | | | | | | | |
| **Hormonal treatment + Radiotherapy** | 121 (49.19%) | | | | | | | | |
| **Hormonal treatment (surgical & medical castration)** | 52 (21.15%) | | | | | | | | |
| **Radiotherapy (palliative)** | 22 (8.94%) | | | | | | | | |
| **Chemotherapy** | 16 (6.5%) | | | | | | | | |
| **Surveillance** | 14 (5.69%) | | | | | | | | |
| **Surgery + Radiotherapy** | 9 (3.66%) | | | | | | | | |
| **Surgery**  **(Radical prostatectomy)** | 7 (2.84%) | | | | | | | | |
| **Surgery + Hormonal treatment + Radiotherapy** | 5 (2.03%) | | | | | | | | |
| **Treatment response** | **Overall** | **Complete** | | **Partial** | | | **Stabledisease** | | **Progressive disease** |
| **Radiotherapy** | 19 (7.72%) | 12 (4.88%) | | 7 (2.85%) | | | 2 (9.09%) | | 1 (4.55%) |
| **Hormonal treatment + Radiotherapy** | 102 (41.46%) | 23 (9.35%) | | 79 (32.11%) | | | 13 (10.74%) | | 6 (4.96%) |
| **Hormonal treatment** | 43 (17.48%) | 14 (5.69%) | | 29 (11.79%) | | | 6 (11.54%) | | 3 (5.77%) |
| **Surgery + Radiotherapy** | 7 (2.85%) | 6 (2.44%) | | 1 (0.4%) | | | 2 (22.22%) | | 0 (0%) |
| **Chemotherapy** | 10 (4.07%) | 2 (0.81%) | | 8 (3.25%) | | | 4 (25%)1 | | 2 (12.5%) |
| **Years** | **Overall survival (%)** | | | | | **Disease free survival (%)** | | | |
| 2 -year | 62.19 | | | | | 55.28 | | | |
| 3 -year | 58.74 | | | | | 52.91 | | | |
| 5 -year | 50.48 | | | | | 45.63 | | | |

Data was presented as Mean ± SD.

Table 4: Distribution of kidney cancer patients according to age, pathological subtypes, stage, treatment approach, treatment response according to treatment modality, overall survival and disease-free survival in kidney cancer

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Age group (year)** | **Total (n =50)** | | | | | |
| 20-40 | 3 (6%) | | | 60.6 ± 10.7 | | |
| 41-60 | 19 (38%) | | |
| 61-80 | 28 (56%) | | |
| >80 | 0 (0%) | | |
| **Pathology** | | | | | | |
| **Renal cell carcinoma** | 46 (92%) | | | | | |
| **Transitional cell carcinoma** | 3 (6%) | | | | | |
| **Oncocytoma** | 1 (2%) | | | | | |
| **Stage** | | | | | | |
| **Stage I** | 3 (6%) | | | | | |
| **Stage II** | 6 (12%) | | | | | |
| **Stage III** | 14 (28%) | | | | | |
| **Stage IV** | 27 (54%) | | | | | |
| **Treatment** | | | | | | |
| **Surgery + Targeted therapy** | 17 (34%) | | | | | |
| **Surgery + Radiotherapy** | 13 (26%) | | | | | |
| **Surgery alone** | 12 (24%) | | | | | |
| **Targeted therapy** | 5 (10%) | | | | | |
| **Surgery + Chemotherapy** | 2 (4 %) | | | | | |
| **Radiotherapy + Targeted therapy** | 1 (2 %) | | | | | |
| **Treatment response** | **Overall** | **Complete** | **Partial** | | **Stabledisease** | **Progressive disease** |
| **Surgery + Radiotherapy** | 12 (24%) | 8 (16%) | 4 (8%) | | 1 (7.69%) | 0 (0%) |
| **Surgery + Targeted therapy** | 15 (30%) | 7 (14%) | 8 (16%) | | 1 (5.88%) | 1 (5.88%) |
| **Surgery alone** | 10 (20%) | 6 (12%) | 4 (8%) | | 2 (16.67%) | 0 (0%) |
| **Years** | **Overall survival (%)** | | | | **Disease free survival (%)** | |
| 2 -year | 56 | | | | 40 | |
| 3 -year | 46.80 | | | | 36.17 | |
| 5 -year | 35.48 | | | | 29.03 | |

Data was presented as Mean ± SD

Table 5 shows distribution of testicular cancer patients according to age, histopathological subtypes, increased tumor markers, stage, treatment approach, treatment response according to treatment modality, overall survival and disease-free survival in testicular cancer.

Table 5: Distribution of testicular cancer patients according to age, histopathological subtypes, increased tumor markers, stage, treatment approach, treatment response according to treatment modality, overall survival and disease-free survival in testicular cancer

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Age group (year)** | **Total (n =10)** | | | | | |
| 20-40 | 7 (70%) | | | 39.3 ± 13.9 | | |
| 41-60 | 1 (10%) | | |
| 61-80 | 2 (20%) | | |
| >80 | 0 (0 %) | | |
| **Pathology** | | | | | | |
| **Seminoma** | 5 (50%) | | | | | |
| **Mixed germ cell** | 3 (30%) | | | | | |
| **Non-seminoma** | 1 (10%) | | | | | |
| **Sarcoma** | 1 (10%) | | | | | |
| **Tumor marker** | | | | | | |
| **LDH** | 6 (60%) | | | | | |
| **HCG** | 3 (30%) | | | | | |
| **α-feto protein** | 4 (40%) | | | | | |
| **Stage** | | | | | | |
| **Stage I** | 3 (30%) | | | | | |
| **Stage II** | 4 (40%) | | | | | |
| **Stage III** | 3 (30%) | | | | | |
| **Treatment** | | | | | | |
| **Surgery (orchiectomy)** | 10 (100%) | | | | | |
| **Surgery + Chemotherapy** | 7 (70%) | | | | | |
| **Surgery + Chemotherapy + Radiotherapy** | 2 (20%) | | | | | |
| **Surgery + Radiotherapy** | 1 (10%) | | | | | |
| **Treatment response** | **Overall response** | **Complete response** | **Partial response** | | **Stable**  **disease** | **Progressive disease** |
| **Surgery + Radiotherapy** | 1 (10%) | 1 (10%) | 0 (0%) | | 0 (0%) | 0 (0%) |
| **Surgery + Chemotherapy** | 6 (60%) | 5 (50%) | 1 (10%) | | 1 (14.29%) | 0 (0%) |
| **Surgery + Radiotherapy + Chemotherapy** | 2 (20%) | 2 (20%) | 0 (0%) | | 0 (0%) | 0 (0%) |
| Years | **Overall survival (%)** | | | **Disease free survival (%)** | | |
| 2 -year | 100 | | | 100 | | |
| 3 -year | 100 | | | 80 | | |
| 5 -year | 80 | | | 70 | | |

Data was presented as Mean ± SD. HCG: Human chorionic gonadotropin, LDH: Lactate dehydrogenase

# 4. Discussion

Male genital tract tumors account for a fairly large number of malignancies. Incidence of male genital cancer has increased rapidly over the period of time [10]**.**

The data at our department showed that bladder cancer is the most common male genitourinary malignancies followed by prostate cancer then kidney cancer and testicular cancer with a percentage 49.8%, 40.3%, 8.2% & 1.6% respectively.

Similar findings were found in Sub-Himalayan region where Panwar et al. [11] found that the bladder cancer ranks the first male genitourinary malignancies followed by prostate cancer then kidney cancer with a percentage of 61.1%, 24.2% & 8.8% respectively.

In contrast, in Port Harcourt, Nigeria, Ofuru et al. [12] found in their study that the most common male genitourinary malignancies were prostate cancer followed by bladder cancer then kidney cancer and testicular cancer with percentage 86.8% ,6.5%, 5.7% & 0.6 % respectively.

We found that the age group mainly affected was 61-80 years followed by age group 41-60 years. More than 95% of patients were more than 41 years old.

Tolou\_Ghamari et al. [13] found that the mean age ± SD was 63.5 ± 15.8 years. The most occurrences of cancers (82%) were at the ages between 50 and 90 years old of patients’ life.

In the present study, the highest frequency of patients was found from gharbia governorate which represented 464 patients (76%) of all studied patients & most common administrative areas were Tanta and Al-Mahalla El Kobra which represented 43.5 % & 37.5 % respectively from all gharbia patients.

In our study we found that most common comorbidity with male genitourinary tumors was hypertension followed by diabetes mellitus then liver cirrhosis. About more than 40% of all male genito- urinary malignancies were smokers. Bilhareziasis was found in patients with bladder cancer with a percentage 7.6%. El-Bolkainy N. et al. [14] reported in their study that the percentage of bladder cancer cases associated with schistosomiasis at the Cairo Cancer Institute were 27.6%. Sow et al. [15]reported in their study that bladder bilharziomas represented 8.8% of bladder cancer patients which is comparable to our results.

Regarding bladder cancer, in our study we found that the most common age group affected by bladder cancer was 61-80 year with mean age 65.9 ± 9.4 years. This is similar to in the Nile delta region of Egypt where fedewa et al. [16] reported that the most common age affected by bladder cancer was 60–69 years.

In our study we found that the most common pathology in bladder cancer was transitional cell carcinoma with a percentage 96.1 % of all bladder cancers. Also in Lebanon, Lakkis et al. [17] reported in their study that transitional cell carcinoma is the most common type of bladder cancer.

In our study we found that the most common stages in bladder cancer was advanced stages (II, III & IV) which represented muscle invasive bladder cancer. The most common one of them was stage IV which represented 47.36% of all bladder cancer cases. At Aristide Le Dantec University Teaching Hospital, Sow et al [15] reported in their study that the majority of tumors were infiltrative (pT2, pT3, pT4) (66.2%) while in Benin, Nigeria Forae et al. [18] reported in their study that early pathological stages accounted for 70.3% while late-stage cancer accounted for 29.7%.

In our study we found that all patients underwent surgery either TUR for diagnosis in 297 cases (97.7%) or radical cystectomy in 7 cases (2.3%), the most common type of treatment used after surgery was chemotherapy in 127 cases (41.77.5%) followed by combined chemo and radio therapy in 125 cases (41.18%).Sow et al. [15] found in their study that active treatments included radical cystectomy in 20 patients (13.3%) and radiotherapy in 40 patients (26.7%). The remaining 90 patients (60%) underwent transurethral resection of the bladder tumor only and refused further treatment.

In the current study, the highest overall response was with patients treated with combined chemo and radiotherapy in 117 (38.49%) patients. In our study 2, 3, and 5-year overall survival in bladder cancer patients was 62.17%, 58.8%, and 50.7% respectively, while the 2, 3, and 5-year disease free survival in bladder cancer patients was 56.58%, 51.31%, and 47.89% respectively

This is comparable to Kaufman et al. [19] who reported that 81% complete response and 5-year overall survival rate of 56% after the using combined radio and chemotherapy in bladder cancer.

Regarding prostate cancer, in our study we found that the most common age group affected by prostate cancer was 61-80 year with mean age 70.2 year & SD ± 7.7. This is comparable to in alexanderia where Elabbady et al. [20] reported in their study that the mean age for prostate cancer was 67 year.

In our study we reported that the most common pathology in prostate cancer was prostatic adenocarcinoma with a percentage 99.2% of all prostate cancers. This is in similar to Ahmadu Bello University Teaching Hospital (A.B.U.T.H), Zaria, Nigeria where Oluwole et al. [21] found in their study that all prostate cancer patients were adenocarcinomas.

In our study we found that the most common gleason score in prostate cancer was (8-10) with a percentage of 48 % of all prostate cancers. This is similar to In Manipur, where Desai et al. [22] found that the commonest gleason score found in prostate cancer was (8-10) with a percentage of 48%.

In our study we found that the most common PSA level in prostate cancer patients is >20 which represented 91% of all prostate cancer patients. This is in similar to in alexanderia where Elabbady et al. [20] reported in their study that the majority of cases were with PSA > 20. And in contrast to Fall et al [23] who reportedthat based on their study which included T1 and T2 prostate cancer patients at baseline with a PSA level of >20 (ng/ml) were 18% of patients, from 10 to 20 were 30% of patients and less than 10% were 52% of patients.

In our study we found that the most common stages of prostate cancer were advanced stages (Stage III & IV which represented collectively 87.85%), stage IV which represented 75.6% followed by stage III which represented 12.25 of all prostate cancers. This is comparable to that in Calabar, South-South, Nigeria where Bassey et al. [24] found in their study that most patients (72, 64.8%) had at least stage 2B and above and in contrast to In Pennsylvania where Merriel et al. [25] found in their study that T1 & T2 stages represented around 72.8% while T3&T4 stages represented around 27.17% of all prostate cancer patients.

In our study we found that the most common treatment approach used was hormonal treatment plus radiotherapy in 121 cases (49.19%) followed by hormonal treatment alone in 52 cases (21.15%) then radiotherapy in 22 cases (8.94%) and surgery done in 21 cases (8.53%) either alone or with other treatment modality then chemotherapy in 16 cases (6.5%). This is comparable to In Calabar, South, where Nigeria-South Bassey et al. [24] found in their study that over half of the patients were placed on antiandrogens for treatment and in contrast to Cooperberg et al. [26] who found in their study that regarding treatment of prostate cancer, 44.7% underwent prostatectomy, 22.0% surveillance, 19.5% radiation (RT), 8.8% androgen deprivation, and 3.6% watchful waiting (WW). This may be due to most of our patients were advanced stages.

In our study we found that the highest overall response was with patients treated with Hormonal treatment + Radiotherapy in 41.46% patients, while 10.74% patients had stable disease and 4.96% patients had progressive disease, followed by hormonal treatment in 17.48% patients, while 11.54% patients had stable disease and 5.77% patients had progressive disease. overall response in patients treated with chemotherapy was in 4.07% patients and we found that 2, 3, and 5-year overall survival in prostate cancer patients was 62.19%, 58.74% and 50.48% respectively while the 2, 3, and 5-year disease free survival in prostate cancer patients and it was 55.28%, 52.91% and 45.63% respectively.

In our study the total overall response in patients treated with hormonal treatment either alone or with radiotheapy was 58.9%, this is comparable to Akaza et al. [27] included 205 Japanese men with prostate cancer treated with hormonal therapy and they reported an overall response rate from 65% to 77% according to type of hormal therapy used and reported that the number of deaths is too small to assess survival. Choueiri et al., [28] fount in their study that that 5 year overall survival for prostate cancer patients was 59%.

Regarding kidney cancer, in our study we found that the most common age group affected by kidney cancer was 61-80 year with mean age 60.6 year & SD ± 10.7. This is comparable to that in Manipur where Desai et al. [22] found in their study that the mean age for kidney cancer was 63.7 year.

In our study we found that the most common pathology in kidney cancer was renal cell carcinoma with a percentage 92% of all kidney cancers. This is similar to in Manipur, where Desai et al. [22] found in their study that the most common pathology was renal cell carcinoma.

In our study we found that the most common stages in kidney cancer was advanced stages, stage IV which represented 54% followed by stage III which represented 28% of all kidney cancer patients. This was similar to Joshi et al. [29] found in their study that the most common stage was stage IV which represented 43% followed by stage III which represented 26% of all kidney cancer patients.

In our study we found that the most common used treatment method was surgery which was done in 44 patients (88%) and used in combination with other modalities as surgery + targeted therapy in 17 (34%) cases followed by surgery + radiotherapy in 13 (26%) cases or surgery alone in 12 (24%) cases. This is similar to that in a Semi-urban population of south-western nigeria, Salako et al. [30] reported in their study that they offered surgery to almost all of their kidney cancer patients (92.2%).

In our study we found that the highest overall response was with patients treated with surgery + targeted therapy in 15 (30%) patients followed by surgery + radiotherapy in 12 (24%) patients. 2, 3, and 5-year overall survival in kidney cancer patients was 56%, 46.8%, and 35.48% respectively. while the 2, 3, and 5-year disease free survival in kidney cancer patients, and it was 40%, 36.17%, and 29.03% respectively. This is comparable to Kroeger, N. et al. [31] who found that 5 year disease free survival in kidney cancer patients was 26%**.**

Regarding testicular cancer, in our study we found that the most common age group affected by testicular cancer was 20-40 year with mean age 39.3 year & SD ± 13.9. This is comparable to taht in Manipur where Desai et al. [22] found in their study that the mean age for testicular cancer was 35 years

In our study we found that the most common pathology in testicular cancer was seminoma with a percentage of 50% followed by mixed germ cell tumors with a percentage 30% of all testicular cancers. This is similar to that in Manipur where Desai et al. [22] found in their study that the most common pathology found in testicular cancer was seminoma .In contrast to in ile-ife, south-western nigeria where Igbokwe et al. [32] found in their study that the most common pathology found in testicular cancer was mixed germ cell tumors with percentage of 38.4% followed by seminoma with a percentage of 30.8% of all testicular cancer pathology.

In our study we found that the most common increased tumor marker was LDH in 6 (60%) patients followed by α-feto protein in 4 (40%) patients. This is similar to Islam et al. [33] who reported that Lactate dehydrogenase (LDH) is the most common marker in seminoma.

In our study we found that the most common stages in testicular cancer was stage II which represented 40% followed by stage I & stage III, each of them represented 30% of all testicular cancer patients. So we have about 70% of our patient with stage I & II, this is comparable to Stevenson et al. [34] who found that nearly70-80 % of patients with low stage testicular tumours.

In our study, the most treatment modality used was surgical treatment which done in all cases (100%) followed by surgery + chemotherapy in 7 (70%) patients. This is comparable to Lubberts et al. [35] who reported that Chemotherapy used in stage I, II & III testicular cancer & this support our result that 90% of our patient received chemotherapy.

In the current study we found that the highest overall response was with patients treated with surgery + chemotherapy in 6 (60%) patients followed by surgery + radiotherapy + chemotherapy in 2 (20%) patients. We also found that 2, 3, and 5-year overall survival in testicular cancer patients, it was 100%, 100%, and 80% respectively while the 2, 3, and 5-year disease free survival in testicular cancer patients, it was 100%, 80%, and 70% respectively. Feldman et al. [36] found that the overall survival rate for testicular cancer was more than 95%, but only 80% for metastatic disease**.**

Conclusions:

We conclude that the most common types of male genito-urinary malignancies included: bladder cancer, prostate cancer, kidney cancer, testicular cancer. The most common histo-pathological subtype in bladder cancer was transitional cell carcinoma, while in prostate cancer was prostatic adenocarcinoma, in kidney cancer was renal cell carcinoma and in testicular cancer was seminoma.

**Financial support and sponsorship:** Nil

**Conflict of Interest:** Nil

References:

1. Pai RK, Van Booven DJ, Parmar M, Lokeshwar SD, Shah K, Ramasamy R, et al. A review of current advancements and limitations of artificial intelligence in genitourinary cancers. Am J Clin Exp Urol. 2020;8:152-62.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
3. Moussa S, El-Sheshtawy W. Pathological pattern of urinary bladder cancer: Data from a single egyptian institute. Oncol Res. 2017;13:14-7.
4. Zheng YL, Amr S, Saleh DA, Dash C, Ezzat S, Mikhail NN, et al. Urinary bladder cancer risk factors in Egypt: a multicenter case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21:537-46.
5. Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7:9-15.
6. Abdel-Rahman O. Impact of histological subtype on outcomes of renal cell carcinoma patients. J Drug Assess. 2018;7:14-20.
7. Scelo G, Larose TL. Epidemiology and risk factors for kidney cancer. J Clin Oncol. 2018;36:2018-22.
8. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. EAU guidelines on testicular cancer: 2011 update. Actas Urol Esp. 2012;36:127-45.
9. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132-7.
10. Maitland NJ. Resistance to antiandrogens in prostate cancer: Is it inevitable, intrinsic or induced? Cancers (Basel). 2021;13:57-62.
11. Panwar R, Gulati A, Kaushik R, Kaushal V, Raina P. Spectrum of urogenital tumors in males in Sub-Himalayan region: An institutional experience. Journal of cancer research and therapeutics. 2019;15:82.
12. Ofuru V, Ekeke N, Obiorah C. Genitourinary malignancies in Port Harcourt, Nigeria. PMJ. 2017;11:10-5.
13. Tolou\_Ghamari Z, Mazdak H, Saboori M, Sichani MM. Genitourinary tract cancers: Frequency and demographic characteristics. Clin Cancer Investig J. 2019;8:232-7.
14. El-Bolkainy N, El-Bolkainy T, Mandour E, Badawy O, Abdelbaky H, El-Attar I. The nonbilharzial urothelial carcinoma in Egypt: analysis of risk factors of stage progression in 530 patients. Egypt J Pathol. 2018;38:22-6.
15. Sow O, Ndiaye M, Ndiath A, Sarr A, Sine B, Ondo C. Histopathological profile of bladder tumors at aristide le dantec university teaching hospital. Med Surg Urol. 2021;10:247-55.
16. Fedewa SA, Soliman AS, Ismail K, Hablas A, Seifeldin IA, Ramadan M, et al. Incidence analyses of bladder cancer in the Nile delta region of Egypt. Cancer Epidemiol. 2009;33:176-81.
17. Lakkis NA, Adib SM, Hamadeh GN, El-Jarrah RT, Osman MH. ‎25-year trends in stage-specific incidence rates for bladder ‎cancer in a large statewide registry. . Can Cont. 2020;25:445–51.
18. Forae GD, Ugiagbe EE, Mekoma DF. A descriptive study of bladder tumors in Benin City, Nigeria: An analysis of histopathological patterns. Saudi Surg J. 2016;4:113-8.
19. Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ, 3rd, Toonkel LM, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73:833-7.
20. Elabbady A, Eid A, Fahmy A, Kotb AF. Pattern of prostate cancer presentation among the Egyptian population: A study in a single tertiary care center. Cent European J Urol. 2014;67:351-6.
21. Oluwole O, Rafindadi A, Shehu M, Samaila M. A ten-year study of prostate cancer specimens at Ahmadu Bello University Teaching Hospital (ABUTH), Zaria, Nigeria. Afr J Urol. 2015;21:15-8.
22. Desai FS, Hospital HC, Singh LS. Evaluation of urological cancers characteristics in Manipur-Are ‎they different from other regions of India ? Evaluation of ‎urological cancers characteristics in Manipur-Are they different ‎from other regions of India ? October.‎. Asian Pac J Cancer Prev. 2015:75-8.
23. Fall K, Garmo H, Andrén O, Bill-Axelson A, Adolfsson J, Adami HO, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007;99:526-32.
24. Bassey I, Isiwele EM, Debua A. Prognostication studies of prostate cancer in black Africa: Findings from Calabar, South-South, Nigeria. Int J Cont Med Res. 2018;5:1-5.
25. Merriel SWD, Turner EL, Walsh E, Young GJ, Metcalfe C, Hounsome L, et al. Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). BMJ open. 2017;7:15-9.
26. Cooperberg M, Fang R, Wolf J, J Stuart, Hubbard H, Pendharkar S, Gupte S, et al. PNFBA-07 The current management of prostate cancer in the united states: data from the aqua registry. J Urol. 2017;197:911-2.
27. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, et al. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol. 2004;34:86-9.
28. Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S. Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int. 2018;100:251-62.
29. Joshi A, Anand A, Prabhash K, Noronha V, Shrirangwar S, Bakshi G, et al. Kidney cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. Indian J Cancer. 2017;54:601-4.
30. Salako A, Badmus T, Badmos K, David R, Laoye A, Akinbola I, et al. Renal cell carcinoma in a semi-urban population of south-western Nigeria. East Afr Med J. 2017;94:37-43.
31. Kroeger N, Choueiri TK, Lee J-L, Bjarnason GA, Knox JJ, MacKenzie MJ, et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol. 2014;65:1086-92.
32. Igbokwe M, Badmus T, Salako A, Komolafe A, David R, Omoyiola O, et al. Histomorphological pattern of urologic malignancies in Ile-Ife, south-western Nigeria. Ann Ib Postgrad. 2020;18:60-4.
33. Islam SR, Rahman S, Boksh Z, Pasha K, Tanim SA. Testicular tumour - a review article. Mymensingh Med J. 2015;24:207-14.
34. Stevenson SM, Lowrance WT. Epidemiology and diagnosis of testis cancer. Urologic Clinics. 2015;42:269-75.
35. Lubberts S, Meijer C, Demaria M, Gietema JA. Early ageing after cytotoxic treatment for testicular cancer and cellular senescence: Time to act. Crit Rev Oncol Hematol. 2020;151:102-9.
36. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008;299:672-84.

6/22/2022